Cell Div. 2007 May 9;2:13.

p27kip1: a target for tumor therapies?

Nickeleit I, Zender S, Kossatz U, Malek NP.

Source

Institute for Molecular Biology, Hannover Medical School, Hannover, Germany. Nickeleit.Irina@MH-Hannover.de

Abstract

The cyclin kinase inhibitor p27kip1 acts as a potent tumor supressor protein in a variety of human cancers. Its expression levels correlate closely with the overall prognosis of the affected patient and often predict the outcome to different treatment modalities. In contrast to other tumor suppressor proteins p27 expression levels in tumor cells are frequently regulated by ubiquitin dependent proteolysis. Re-expression of p27 in cancer cells therefore does not require gene therapy but can be achieved by interfering with the protein turnover machinery. In this review we will summarize experimental results which highlight the potential use of p27 as a target for oncological therapies.

PMID:: 17488529; [PubMed]
PMCID: PMC1872022

Free PMC Article

LinkOut - more resources

Full Text Sources

Libraries

LinkOut Holdings

Supplemental Content

Related citations

Pirh2 promotes ubiquitin-dependent degradation of the cyclin-dependent kinase inhibitor p27Kip1. [Cancer Res. 2007]
Pirh2 promotes ubiquitin-dependent degradation of the cyclin-dependent kinase inhibitor p27Kip1.
Hattori T, Isobe T, Abe K, Kikuchi H, Kitagawa K, Oda T, Uchida C, Kitagawa M. Cancer Res. 2007 Nov 15; 67(22):10789-95.
Bortezomib (Velcade) induces p27Kip1 expression through S-phase kinase protein 2 degradation in colorectal cancer. [Cancer Res. 2008]
Bortezomib (Velcade) induces p27Kip1 expression through S-phase kinase protein 2 degradation in colorectal cancer.
Uddin S, Ahmed M, Bavi P, El-Sayed R, Al-Sanea N, AbdulJabbar A, Ashari LH, Alhomoud S, Al-Dayel F, Hussain AR, et al. Cancer Res. 2008 May 1; 68(9):3379-88.
EGCG stabilizes p27kip1 in E2-stimulated MCF-7 cells through down-regulation of the Skp2 protein. [Endocrinology. 2008]
EGCG stabilizes p27kip1 in E2-stimulated MCF-7 cells through down-regulation of the Skp2 protein.
Huang HC, Way TD, Lin CL, Lin JK. Endocrinology. 2008 Dec; 149(12):5972-83. Epub 2008 Aug 21.
Review The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. [Nat Rev Cancer. 2008]
Review The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy.
Chu IM, Hengst L, Slingerland JM. Nat Rev Cancer. 2008 Apr; 8(4):253-67.
Review Overview of resistance to systemic therapy in patients with breast cancer. [Adv Exp Med Biol. 2007]
Review Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN. Adv Exp Med Biol. 2007; 608:1-22.

See reviews... See all...

Cited by 7 PubMed Central articles

Chemical genetics approach to restoring p27Kip1 reveals novel compounds with antiproliferative activity in prostate cancer cells. [BMC Biol. 2010]
Chemical genetics approach to restoring p27Kip1 reveals novel compounds with antiproliferative activity in prostate cancer cells.
Rico-Bautista E, Yang CC, Lu L, Roth GP, Wolf DA. BMC Biol. 2010 Dec 23; 8:153. Epub 2010 Dec 23.
S phase entry causes homocysteine-induced death while ataxia telangiectasia and Rad3 related protein functions anti-apoptotically to protect neurons. [Brain. 2010]
S phase entry causes homocysteine-induced death while ataxia telangiectasia and Rad3 related protein functions anti-apoptotically to protect neurons.
Ye W, Blain SW. Brain. 2010 Aug; 133(Pt 8):2295-312. Epub 2010 Jul 17.
Silibinin suppresses growth and induces apoptotic death of human colorectal carcinoma LoVo cells in culture and tumor xenograft. [Mol Cancer Ther. 2009]
Silibinin suppresses growth and induces apoptotic death of human colorectal carcinoma LoVo cells in culture and tumor xenograft.
Kaur M, Velmurugan B, Tyagi A, Deep G, Katiyar S, Agarwal C, Agarwal R. Mol Cancer Ther. 2009 Aug; 8(8):2366-74. Epub 2009 Jul 28.

See all...

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
References for this PMC Article
Citation referenced in PubMed article. Only valid for PubMed citations that are also in PMC.
Free in PMC
Free full text articles in PMC
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

p27kip1: a target for tumor therapies?
p27kip1: a target for tumor therapies?
Cell Div. 2007 May 9 ;2:13.

PubMed
Self-regulated mechanism of Plk1 localization to kinetochores: lessons from the ...
Self-regulated mechanism of Plk1 localization to kinetochores: lessons from the Plk1-PBIP1 interaction.
Cell Div. 2008 Jan 23 ;3:4.

PubMed
"Cullin 4 makes its mark on chromatin".
"Cullin 4 makes its mark on chromatin".
Cell Div. 2006 Jul 10 ;1:14.

PubMed
Tying the loose ends together in DNA double strand break repair with 53BP1.
Tying the loose ends together in DNA double strand break repair with 53BP1.
Cell Div. 2006 Aug 31 ;1:19.

PubMed
Responding to chromosomal breakage during M-phase: insights from a cell-free sys...
Responding to chromosomal breakage during M-phase: insights from a cell-free system.
Cell Div. 2009 Jul 14 ;4:15.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Display Settings:

Send to:

p27kip1: a target for tumor therapies?

Source

Abstract

LinkOut - more resources

Full Text Sources

Libraries

Supplemental Content

Related citations

Cited by 7 PubMed Central articles

Related information

Recent activity

Simple NCBI Directory

Getting Started

Resources

Popular

Featured

NCBI Information